FI965141A - Tulehdussytokiinien inhibiitteinä hyödylliset N-substituoitu-(dihydroksiboryyli)alkyylipuriini-, indoli- ja pyrimidiinijohdannaiset - Google Patents

Tulehdussytokiinien inhibiitteinä hyödylliset N-substituoitu-(dihydroksiboryyli)alkyylipuriini-, indoli- ja pyrimidiinijohdannaiset Download PDF

Info

Publication number
FI965141A
FI965141A FI965141A FI965141A FI965141A FI 965141 A FI965141 A FI 965141A FI 965141 A FI965141 A FI 965141A FI 965141 A FI965141 A FI 965141A FI 965141 A FI965141 A FI 965141A
Authority
FI
Finland
Prior art keywords
indole
dihydroxyboryl
inhibitors
substituted
inflammatory cytokines
Prior art date
Application number
FI965141A
Other languages
English (en)
Swedish (sv)
Other versions
FI965141A0 (fi
Inventor
Bradley J Benson
Xiannong Chen
George J Cianciolo
Jose-Luis Diaz
Khalid S Ishaq
Susan L Morris-Natschke
Ronald J Uhing
Henry Wong
Original Assignee
Macronex Inc
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macronex Inc, Univ North Carolina filed Critical Macronex Inc
Publication of FI965141A0 publication Critical patent/FI965141A0/fi
Publication of FI965141A publication Critical patent/FI965141A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
FI965141A 1994-06-22 1996-12-20 Tulehdussytokiinien inhibiitteinä hyödylliset N-substituoitu-(dihydroksiboryyli)alkyylipuriini-, indoli- ja pyrimidiinijohdannaiset FI965141A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/264,039 US5643893A (en) 1994-06-22 1994-06-22 N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
PCT/US1995/007936 WO1995035300A1 (en) 1994-06-22 1995-06-21 N-substituted-(dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines

Publications (2)

Publication Number Publication Date
FI965141A0 FI965141A0 (fi) 1996-12-20
FI965141A true FI965141A (fi) 1996-12-20

Family

ID=23004300

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965141A FI965141A (fi) 1994-06-22 1996-12-20 Tulehdussytokiinien inhibiitteinä hyödylliset N-substituoitu-(dihydroksiboryyli)alkyylipuriini-, indoli- ja pyrimidiinijohdannaiset

Country Status (16)

Country Link
US (1) US5643893A (fi)
EP (1) EP0767793B1 (fi)
JP (1) JP3805789B2 (fi)
KR (1) KR970703975A (fi)
AT (1) ATE224396T1 (fi)
AU (1) AU2907795A (fi)
CA (1) CA2193644A1 (fi)
DE (1) DE69528267T2 (fi)
DK (1) DK0767793T3 (fi)
ES (1) ES2183877T3 (fi)
FI (1) FI965141A (fi)
HU (1) HUT76298A (fi)
NO (1) NO965521L (fi)
NZ (1) NZ289286A (fi)
PT (1) PT767793E (fi)
WO (1) WO1995035300A1 (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003858A1 (fr) * 1997-07-15 1999-01-28 Japan Energy Corporation Derives purine et leur application medicinale
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
IL147749A0 (en) 1999-07-22 2002-08-14 Newbiotics Inc Methods for treating therapy-resistant tumors
US6586429B2 (en) 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
EP1359921A4 (en) * 2001-01-19 2006-09-06 Newbiotics Inc METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
WO2002072090A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US20030022864A1 (en) * 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) * 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
JP2006517213A (ja) * 2003-02-11 2006-07-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な抗コリン作用剤とTNFα合成又は作用阻害剤に基づく新規な医薬組成物
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
MY146066A (en) * 2004-07-01 2012-06-29 Microlin L C Device employing gas generating cell for facilitating controlled release of fluid into ambient environment
US20080269204A1 (en) * 2004-11-01 2008-10-30 Tatyana Dyakonov Compounds and Methods of Use Thereof
US20090005344A1 (en) * 2004-11-01 2009-01-01 Nkuada, Llc Compounds and Methods of Use Thereof
US20080319044A1 (en) * 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
WO2007134169A2 (en) * 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20090264384A1 (en) * 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2279291B1 (en) 2008-04-09 2019-07-03 Cornell University Coferons and methods of making and using them
JP5637982B2 (ja) * 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ, インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US9771345B2 (en) 2009-10-07 2017-09-26 Cornell University Coferons and methods of making and using them
EP2531511A1 (en) * 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
EP2647639A1 (en) * 2012-04-06 2013-10-09 LEK Pharmaceuticals d.d. ß-boration of alkene and alkyne intermediates
US11078528B2 (en) 2015-10-12 2021-08-03 Advanced Cell Diagnostics, Inc. In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
WO2024054934A1 (en) 2022-09-07 2024-03-14 Mdx Management Llc Shp-1 inhibitors for treating cancer
WO2024097804A1 (en) 2022-11-02 2024-05-10 Mdx Management Llc Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
WO2024196822A1 (en) 2023-03-17 2024-09-26 Mdx Management Llc Compositions and methods for ameliorating adverse effects of therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
GB8926611D0 (en) * 1989-11-24 1990-01-17 Xenova Ltd Compound and its use
US5130302A (en) * 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5362732A (en) * 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
CA2112239C (en) * 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US5306722A (en) * 1992-09-02 1994-04-26 Bristol-Myers Squibb Company Thymidine derivatives and therapeutic method of use

Also Published As

Publication number Publication date
PT767793E (pt) 2003-02-28
NZ289286A (en) 1998-09-24
US5643893A (en) 1997-07-01
AU2907795A (en) 1996-01-15
WO1995035300A1 (en) 1995-12-28
ES2183877T3 (es) 2003-04-01
KR970703975A (ko) 1997-08-09
CA2193644A1 (en) 1995-12-28
JPH10507739A (ja) 1998-07-28
DE69528267D1 (de) 2002-10-24
EP0767793B1 (en) 2002-09-18
NO965521D0 (no) 1996-12-20
EP0767793A1 (en) 1997-04-16
HU9603536D0 (en) 1997-02-28
DK0767793T3 (da) 2002-10-14
FI965141A0 (fi) 1996-12-20
HUT76298A (en) 1997-07-28
JP3805789B2 (ja) 2006-08-09
NO965521L (no) 1997-02-21
ATE224396T1 (de) 2002-10-15
DE69528267T2 (de) 2003-04-17

Similar Documents

Publication Publication Date Title
FI965141A (fi) Tulehdussytokiinien inhibiitteinä hyödylliset N-substituoitu-(dihydroksiboryyli)alkyylipuriini-, indoli- ja pyrimidiinijohdannaiset
FI965140A (fi) Tulehdussytokiinien inhibiitteinä hyödylliset hydroksialkyyliammoniumpyrimidiinit tai puriinit ja nukleosidijohdannaiset
MX9702488A (es) Compuestos de purina y guanina como inhibidores de pnp.
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
EA200201096A1 (ru) СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
GB0217757D0 (en) Novel compounds
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
HRP20050382B1 (hr) Novi pirimidin-4,6-dikarboksamidi za selektivnu inhibiciju kolagenaza
DK0944616T3 (da) Bicykliske arylcarboxamider og deres terapeutiske anvendelse
MY129491A (en) Hydrazono-malonitriles
EA200200558A1 (ru) 2-( 1h-индол-3-ил)-2-оксоацетамиды, обладающие противоопухолевой активностью
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
SE9903290D0 (sv) Novel compounds
NZ334030A (en) Synthesis of bisindolylmalimides
EP0176333A3 (en) Substituted quinazolinediones
IT1201454B (it) 1,4-diidropiridine-2-sostituite
GB0208176D0 (en) Organic compounds
AP2000002001A0 (en) Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the tnf relaease.
IL169334A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
ES8507105A1 (es) Un procedimiento para la preparacion de n-(tio-1-oxopropil)-n-(4-fenilciclohexil)-glicinas.
ES449234A1 (es) Procedimiento para preparar 1-triorgano-estannil-2, 4-dioxo-1, 2, 3, 4-tetrahidro-s-triacino-(1, 2-a)-benzimidazoles sustituidos en la posicion 3.
TH65765A (th) สารยับยั้งไพริมิดีน-2,4,6-ไตรโอนเมททัลโลโพรทีเนส

Legal Events

Date Code Title Description
FD Application lapsed